OTCMKTS:GTHP

Guided Therapeutics Competitors

$0.80
-0.02 (-2.44 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.69
Now: $0.80
$0.83
50-Day Range
$0.71
MA: $0.79
$0.90
52-Week Range
$0.12
Now: $0.80
$1.00
Volume7,439 shs
Average Volume18,461 shs
Market Capitalization$10.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8

Competitors

Guided Therapeutics (OTCMKTS:GTHP) Vs. HSDT, FCRE, CHFS, VIVE, RSLS, and PEYE

Should you be buying GTHP stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Guided Therapeutics, including Helius Medical Technologies (HSDT), Fc Global Realty (FCRE), CHF Solutions (CHFS), Viveve Medical (VIVE), ReShape Lifesciences (RSLS), and Precision Optics (PEYE).

Guided Therapeutics (OTCMKTS:GTHP) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Profitability

This table compares Guided Therapeutics and Helius Medical Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guided TherapeuticsN/A-29.31%502.80%
Helius Medical Technologies-2,716.85%-328.07%-201.87%

Volatility & Risk

Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Guided Therapeutics and Helius Medical Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guided Therapeutics0000N/A
Helius Medical Technologies01202.67

Helius Medical Technologies has a consensus target price of $20.00, suggesting a potential upside of 13.90%. Given Helius Medical Technologies' higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Guided Therapeutics.

Valuation & Earnings

This table compares Guided Therapeutics and Helius Medical Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guided Therapeutics$40,000.00263.60$-1,920,000.00N/AN/A
Helius Medical Technologies$1.50 million27.05$-9,780,000.00($12.94)-1.36

Guided Therapeutics has higher earnings, but lower revenue than Helius Medical Technologies.

Summary

Guided Therapeutics beats Helius Medical Technologies on 6 of the 10 factors compared between the two stocks.

Fc Global Realty (OTCMKTS:FCRE) and Guided Therapeutics (OTCMKTS:GTHP) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Risk & Volatility

Fc Global Realty has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Valuation & Earnings

This table compares Fc Global Realty and Guided Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fc Global Realty$40,000.00971.79$-2,040,000.00N/AN/A
Guided Therapeutics$40,000.00263.60$-1,920,000.00N/AN/A

Profitability

This table compares Fc Global Realty and Guided Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fc Global Realty-4,265.28%-24.94%-9.42%
Guided TherapeuticsN/A-29.31%502.80%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Fc Global Realty and Guided Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fc Global Realty0000N/A
Guided Therapeutics0000N/A

Guided Therapeutics (OTCMKTS:GTHP) and CHF Solutions (NASDAQ:CHFS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Guided Therapeutics and CHF Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guided TherapeuticsN/A-29.31%502.80%
CHF Solutions-254.26%-173.61%-131.01%

Risk & Volatility

Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, CHF Solutions has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Institutional & Insider Ownership

65.1% of CHF Solutions shares are held by institutional investors. 76.3% of Guided Therapeutics shares are held by insiders. Comparatively, 0.6% of CHF Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Guided Therapeutics and CHF Solutions' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guided Therapeutics$40,000.00263.60$-1,920,000.00N/AN/A
CHF Solutions$5.51 million5.84$-18,110,000.00($279.28)-0.02

Guided Therapeutics has higher earnings, but lower revenue than CHF Solutions.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Guided Therapeutics and CHF Solutions, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guided Therapeutics0000N/A
CHF Solutions00103.00

CHF Solutions has a consensus price target of $20.00, indicating a potential upside of 275.23%. Given CHF Solutions' higher possible upside, analysts clearly believe CHF Solutions is more favorable than Guided Therapeutics.

Guided Therapeutics (OTCMKTS:GTHP) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Guided Therapeutics and Viveve Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guided Therapeutics0000N/A
Viveve Medical00103.00

Earnings and Valuation

This table compares Guided Therapeutics and Viveve Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guided Therapeutics$40,000.00263.60$-1,920,000.00N/AN/A
Viveve Medical$6.57 million4.74$-42,530,000.00($338.00)-0.01

Guided Therapeutics has higher earnings, but lower revenue than Viveve Medical.

Profitability

This table compares Guided Therapeutics and Viveve Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guided TherapeuticsN/A-29.31%502.80%
Viveve Medical-661.57%-243.62%-139.23%

Institutional & Insider Ownership

18.2% of Viveve Medical shares are held by institutional investors. 76.3% of Guided Therapeutics shares are held by insiders. Comparatively, 5.0% of Viveve Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Guided Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Viveve Medical has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Summary

Guided Therapeutics beats Viveve Medical on 7 of the 11 factors compared between the two stocks.

Guided Therapeutics (OTCMKTS:GTHP) and ReShape Lifesciences (OTCMKTS:RSLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Guided Therapeutics and ReShape Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guided Therapeutics$40,000.00263.60$-1,920,000.00N/AN/A
ReShape Lifesciences$15.09 million1.80$-74,210,000.00N/AN/A

Guided Therapeutics has higher earnings, but lower revenue than ReShape Lifesciences.

Volatility and Risk

Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares Guided Therapeutics and ReShape Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guided TherapeuticsN/A-29.31%502.80%
ReShape Lifesciences-314.18%-186.31%-101.10%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Guided Therapeutics and ReShape Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guided Therapeutics0000N/A
ReShape Lifesciences00103.00

Summary

Guided Therapeutics beats ReShape Lifesciences on 5 of the 8 factors compared between the two stocks.

Precision Optics (OTCMKTS:PEYE) and Guided Therapeutics (OTCMKTS:GTHP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Precision Optics and Guided Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision Optics0000N/A
Guided Therapeutics0000N/A

Valuation and Earnings

This table compares Precision Optics and Guided Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision Optics$9.92 million2.17$-1,430,000.00N/AN/A
Guided Therapeutics$40,000.00263.60$-1,920,000.00N/AN/A

Precision Optics has higher revenue and earnings than Guided Therapeutics.

Profitability

This table compares Precision Optics and Guided Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision Optics-13.17%-46.31%-22.21%
Guided TherapeuticsN/A-29.31%502.80%

Risk & Volatility

Precision Optics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Summary

Guided Therapeutics beats Precision Optics on 6 of the 8 factors compared between the two stocks.


Guided Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.56-0.7%$40.58 million$1.50 million-1.00Analyst Upgrade
Increase in Short Interest
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10-90.1%$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.33-1.7%$32.18 million$5.51 million-0.11High Trading Volume
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01-0.3%$31.13 million$6.57 million-0.01
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.40-0.0%$27.14 million$15.09 million0.00
PEYE
Precision Optics
0.4$1.62-0.0%$21.49 million$9.92 million-16.20
Vaso logo
VASO
Vaso
0.9$0.09-10.9%$17.02 million$75.75 million4.59Gap Up
STRR
Star Equity
0.1$3.21-2.8%$15.80 million$114.18 million-1.02
Micron Solutions logo
MICR
Micron Solutions
0.3$3.01-4.7%$10.12 million$17.50 million21.50Increase in Short Interest
NIMU
Non-Invasive Monitoring Systems
0.5$0.03-0.0%$2.49 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55-0.0%$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05-0.0%$764,000.00N/A0.00
MAGAA
Magna-Lab
0.7$0.58-90.4%$678,000.00N/A3.19High Trading Volume
Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03-0.0%$367,000.00N/A0.00Gap Up
IMRIS logo
IMRSQ
IMRIS
0.5$0.01-0.0%$364,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00-0.0%$265,000.00N/A0.00Decrease in Short Interest
ULGX
Urologix
0.6$0.01-0.0%$166,000.00N/A0.00Gap Up
AKSY
Aksys
0.0$0.00-0.0%$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.40-25.0%$0.00$9.40 million-6.67Increase in Short Interest
Gap Down
HRTT
Heart Tronics
0.0$0.02-933.3%$0.00N/A0.00High Trading Volume
Gap Up
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00-0.0%$0.00N/A0.00
PECN
Photoelectron
0.2$0.03-0.0%$0.00N/A0.00Increase in Short Interest
Trimedyne logo
TMED
Trimedyne
0.4$4.25-0.2%$0.00$5.57 million0.00News Coverage
XCRP
Xcorporeal
0.0$0.00-0.0%$0.00N/A0.00
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.